Thanks for the support to Hotel Mediterraneo
Via Ponte di Tappia 25 - 80133 Napoli - Tel. +39 081 7970001 e-mail: [email protected] - www. mediterraneonapoli.com
Venue of the Congress
Sede di Milano Via Enrico Nöe, 23 20133 Milano tel. 02 26683129 fax 02 59610555 [email protected]
Sede di Roma Via D. Cimarosa, 18 00198 Roma tel. 06 8553259 fax 06 8553221 [email protected]
Segreteria Organizzativa
Associazione Italiana di Oncologia Medica
Via Enrico Nöe, 23 - 20133 Milano tel. 02 70630279 - fax 02 2360018 [email protected] - www.aiom.it
Segreteria AIOM
SIAPEC-IAP
7 TH MeeTIng On
exTernAl quAlITy ASSeSSMenT In MOleCulAr pATHOlOgy
Hotel Mediterraneo
naples, 11-12 May, 2018
OffICIAl AnnuAl MeeTIng Of IqnpATH
prOgrAM
frIdAy, MAy 11
Chairs: H. vanKrieken and N. Normanno 09.00 Welcome and Opening
S. Gori, M. Truini, F. Ciardiello, A. Bianchi, G. Botti 09.30 - 11.00 Joint ESMO-AIOM-IQN Path session
Cancer immunotherapy: beyond PD-L1 Chairs: G. Beretta, F. Ciardiello, H. van Krieken
The aim of this session is to illustrate the new biomarkers for PD1-PD-L1 inhibitors as well as the new checkpoint inhibitors in clinical development.
09.30 - 09.55 Immunocheckpoint inhibitors in cancer: novel drugs for novel targets (E. Garralda) 09.55 - 10.20 Emerging biomarkers for PD1/PD-L1 inhibitors (J. Gosney)
10.20 - 10.45 The IQNPath initiative for tumor mutation burden (N. Normanno, F. Fenizia) 10.45 - 11.00 Discussion
11.00 - 11.15 Coffee break
11.15 - 13.00 Current status of PD-L1 assessment Chairs: M. Dietel, K. Miller, E. Torlakovic
The aim of this session is to present results from clinical practice and national and international initiatives and EQA schemes to improve PD-L1 assessment in clinical practice. The proposal of IQNPath recommendations for PD-L1 testing will be discussed.
(Speakers will present 5 slides summarizing the activities of the scientific societies in the field.)
• SIAPEC (A. Marchetti)
• Quip (P. Schirmacher)
• CIQC (E. Torlakovic)
• ESP (N.A. ‘t Hart)
• UKNEQAS-ICC&ISH (S. Parry)
• IQNPath Digital slide initiative (S. Wedden)
Discussion focused on the harmonization of EQA initiatives
13.00 - 14.00 Lunch
14.00 - 15.45 The use of liquid biopsy in the management of cancer patients Chairs: S. Deans, E. Dequeker, C. Pinto
In this session, the challenges for the clinical implementation of liquid biopsies in clinical practice will be discussed.
14.00 - 14.20 Which information the laboratory needs to receive from the clinician (A. Oniscu) 14.20 - 14.40 Which information the clinician needs to receive from the lab (F. Morgillo)
14.40 - 15.00 The current status of liquid biopsy testing in Europe: results from European EQA schemes (IQNPATH - C. Keppens, QUIP - S. Merkelbach-Bruse)
15.00 - 15.45 Discussion: focus on EQA issues 15.45 - 17.15 Technology improvements
Chairs: R. Bordonaro, N. Normanno, H. van Krieken
• Agilent
• Qiagen
• Sysmex
• Thermofisher
• Biocartis
17.15 - 17.30 Tea break
17.30 - 18.30 General Meeting IQN Path (open to all IQN Path members)
SATurdAy, MAy 12
09.00 - 10.50 Genetic variants and molecular pathology: somatic, germline or both?
Chairs: M. Dietel, S. Patton, A. Russo
Germline variants are becoming relevant for targeted therapy. Pathogenic germline variants are frequently found in screening programs with next generation sequencing.
This session wants to highlight the increasing convergence of these two apparently different fields.
09.00 - 09.20 BRCA testing in ovarian carcinoma: blood first (S. Banerjee) 09.20 - 09.40 BRCA testing in ovarian carcinoma: tissue first (S. Pignata)
09.40 - 10.00 The relevance of BRCA mutations for target therapy beyond ovarian cancer (G. Daniele) 10.00 - 10.20 EQA results for BRCA testing (S. Patton, M. Dietel)
10.20 - 10.50 Discussion: focus based on EQA for BRCA testing 10.50 - 11.10 Coffee break
11.10 - 13.30 Restricted session of IQN Path academic members on the update of
recommendations for EQA schemes and other activities (H. van Krieken, E. Dequeker) 13.30 - 14.30 Lunch
